The company’s loss from operations was $7.39m, compared to $5.76m for the same period last year.
Total operating expenses for the first quarter ended 31 March 2011 were $7.39m, as compared to $5.76m for the same period in 2010.
Research and development expenses were $6.1m for the first quarter of 2011 compared to $4.5m for the first quarter of 2010.
The increase in research and development expenses primarily reflects an increase in clinical trial expenses related to anticancer agent TH-302.